The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-relatedmacular degeneration

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 2, 2015, Pages 1335-1348

  Hollanders, Karolien ^a   Van Bergen, Tine ^a   Kindt, Nele ^b   Castermans, Karolien ^b   Leysen, Dirk ^b   Vandewalle, Evelien ^a,c   Moons, Lieve ^a,c   Stalmans, Ingeborg ^a,c  

^a KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

^b Amakem Therapeutics   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Age related macular degeneration; Anti vascular endothelial growth factor; Rho kinase inhibition

Indexed keywords

AMA 0428; PLACENTAL GROWTH FACTOR; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ENZYME INHIBITOR; RHO KINASE; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HUMAN; HUMAN CELL; INFLAMMATION; LASER MICROSCOPY; MALE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBRETINAL NEOVASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; CELL MOTION; COMPLICATION; DISEASE MODEL; MACULAR DEGENERATION; METABOLISM; PATHOLOGY; RETINAL NEOVASCULARIZATION;

ANIMALS; APOPTOSIS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; MACULAR DEGENERATION; MALE; MICE; MICE, INBRED C57BL; RETINAL NEOVASCULARIZATION; RHO-ASSOCIATED KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84927173107     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-15681     Document Type: Article

References (83)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291: 1900-1901.
2. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358: 2606-2617.
3. Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009;18: 1573-1580.
4. Bressler NM. Early detection and treatment of neovascular agerelated macular degeneration. J Am Board Fam Pract. 2002;15: 142-152.
5. Lassota N. Clinical and histological aspects of CNV formation: studies in an animal model. Acta Ophthalmol. 2008;86: 1-24.
6. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2004;242: 91-101.
7. Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell. 2009;141: 178-190.
8. de Oliveira Dias JR, Rodrigues EB, Maia M, Magalhães O Jr, Penha FM, Farah ME. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol. 2011;95: 1631-1637.
9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
10. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1432-1444.
11. Kim I, Ryan AM, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999;40: 2115-2121.
12. Tobin KA. Macugen treatment for wet age-related macular degeneration. Insight. 2006;31: 11-14.
13. Fraunfelder FW. Pegaptanib for wet macular degeneration. Drugs Today (Barc). 2005;41: 703-709.
14. Semeraro F, Morescalchi F, Parmeggiani F, Arcidiacono B, Costagliola C. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. Curr Vasc Pharmacol. 2011;9: 629-646.
15. Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell Mol Life Sci. 2010;67: 171-177.
16. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21: 247-269.
17. Danen EH, van Rheenen J, Franken W, et al. Integrins control motile strategy through a Rho-cofilin pathway. J Cell Biol. 2005;169: 515-526.
18. Wang S, Cao C, Chen Z, et al. Pericytes regulate vascular basement membrane remodeling and govern neutrophil extravasation during inflammation. PLoS One. 2012;7: e45499.
19. Bondjers C, Kalen M, Hellstrom M, et al. Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells. Am J Pathol. 2003;162: 721-729.
20. Montanez E, Wickstrom SA, Altstatter J, Chu H, Fassler R. Alpha-parvin controls vascular mural cell recruitment to vessel wall by regulating RhoA/ROCK signalling. EMBO J. 2009;28: 3132-3144.
21. Ren XD, Kiosses WB, Schwartz MA. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J. 1999;18: 578-585.
22. Honjo M, Tanihara H, Kameda T, Kawaji T, Yoshimura N, Araie M. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007;48: 5549-5557.
23. Liu M, Gu M, Wu Y, et al. Therapeutic effect of Y-27632 on chronic allograft nephropathy in rats. J Surg Res. 2009;157: e117-e127.
24. Arita R, Hata Y, Ishibashi T. ROCK as a therapeutic target of diabetic retinopathy. J Ophthalmol. 2010;2010: 175163.
25. Doe C, Bentley R, Behm DJ, et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007;320: 89-98.
26. Mong PY, Wang Q. Activation of Rho kinase isoforms in lung endothelial cells during inflammation. J Immunol. 2009;182: 2385-2394.
27. Coleman HR, Chan CC, Ferris FL III, Chew EY. Age-related macular degeneration. Lancet. 2008;372: 1835-1845.
28. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol. 2004;137: 496-503.
29. Wang Y, Wang VM, Chan CC. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye. 2011;25: 127-139.
30. Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res. 2010;29: 95-112.
31. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and agerelated macular degeneration. Prog Retin Eye Res. 2001;20: 705-732.
32. Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol. 2008;30: 97-110.
33. Boland S, Defert O, Alen J, et al. 3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors. Bioorg Med Chem Lett. 2013;23: 6442-6446.
34. Bryan BA, Dennstedt E, Mitchell DC, et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 2010;24: 3186-3195.
35. Castermans K, Tabruyn SP, Zeng R, et al. Angiostatic activity of the antitumor cytokine interleukin-21. Blood. 2008;112: 4940-4947.
36. Zheng Y, Bando H, Ikuno Y, et al. Involvement of rho-kinase pathway in contractile activity of rabbit RPE cells in vivo and in vitro. Invest Ophthalmol Vis Sci. 2004;45: 668-674.
37. Ryan SJ. The development of an experimental model of subretinal neovascularization in disciform macular degeneration. Trans Am Ophthalmol Soc. 1979;77: 707-745.
38. Dobi ET, Puliafito CA, Destro M. A new model of experimental choroidal neovascularization in the rat. Arch Ophthalmol. 1989;107: 264-269.
39. Tobe T, Ortega S, Luna JD, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 1998;153: 1641-1646.
40. Bocci G, Man S, Green SK, et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 2004;64: 6616-6625.
41. Bocci G, Danesi R, Marangoni G, et al. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Eur J Pharmacol. 2004;498: 9-18.
42. Lambert V, Munaut C, Jost M, et al. Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am J Pathol. 2002;161: 1247-1253.
43. Li Z, Van Bergen T, Van de Veire S, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2009;50: 5217-5225.
44. Van Bergen T, Vandewalle E, Van de Veire S, et al. The role of different VEGF isoforms in scar formation after glaucoma filtration surgery. Exp Eye Res. 2011;93: 689-699.
45. Van Bergen T, Marshall D, Van de Veire S, et al. The role of LOX and LOXL2 in scar formation after glaucoma surgery. Invest Ophthalmol Vis Sci. 2013;54: 5788-5796.
46. Poor SH, Qiu Y, Fassbender ES, et al. Reliability of the mouse model of choroidal neovascularization induced by laser photocoagulation. Invest Ophthalmol Vis Sci. 2014;55: 6525-6534.
47. Van Bergen T, Jonckx B, Hollanders K, et al. Inhibition of placental growth factor improves surgical outcome of glaucoma surgery. J Cell Mol Med. 2013;17: 1632-1643.
48. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456: 809-813.
49. Krause TA, Alex AF, Engel DR, Kurts C, Eter N. VEGFproduction by CCR2-dependent macrophages contributes to laser-induced choroidal neovascularization. PLoS One. 2014;9: e94313.
50. Huang H, Shen J, Vinores SA. Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye. PLoS One. 2011;6: e21411.
51. Caballero S, Yang R, Grant MB, Chaqour B. Selective blockade of cytoskeletal actin remodeling reduces experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2011;52: 2490-2496.
52. Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol. 2007;91: 1230-1233.
53. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology. 2009;116: e1221.
54. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171: 53-67.
55. Hollanders K, Van Bergen T, Van de Velde S, et al. Bevacizumab revisited: its use in different mouse models of ocular pathologies. Curr Eye Res. 2014;1-11.
56. Bryan BA, Dennstedt E, Mitchell DC, et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 2010;24: 3186-3195.
57. van Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol. 2003;23: 211-217.
58. van der Meel R, Symons MH, Kudernatsch R, et al. The VEGF/ Rho GTPase signalling pathway: a promising target for antiangiogenic/ anti-invasion therapy. Drug Discov Today. 2011;16: 219-228.
59. Hoang MV, Whelan MC, Senger DR. Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci U S A. 2004;101: 1874-1879.
60. Zeng H, Zhao D, Mukhopadhyay D. KDR stimulates endothelial cell migration through heterotrimeric G protein Gq/11- mediated activation of a small GTPase RhoA. J Biol Chem. 2002;277: 46791-46798.
61. Aepfelbacher M, Essler M, Huber E, Sugai M, Weber PC. Bacterial toxins block endothelial wound repair. Evidence that Rho GTPases control cytoskeletal rearrangements in migrating endothelial cells. Arterioscler Thromb Vasc Biol. 1997;17: 1623-1629.
62. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273: 245-248.
63. Feng J, Ito M, Ichikawa K, et al. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem. 1999;274: 37385-37390.
64. Huang H, Parlier R, Shen JK, Lutty GA, Vinores SA. VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV. PLoS One. 2013;8: e71808.
65. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44: 3186-3193.
66. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11: 83-95.
67. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24: 16-24.
68. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005;23: 8136-8139.
69. Fazal MA, Saksena J, Haddad FS. Temporary coracoclavicular screw fixation for displaced distal clavicle fractures. J Orthop Surg (Hong Kong). 2007;15: 9-11.
70. Zhang B, Yan L, Fazal I, et al. Slow light on Gbit/s differentialphase- shift-keying signals. Opt Express. 2007;15: 1878-1883.
71. Arita R, Nakao S, Kita T, et al. A key role for ROCK in TNFalpha- mediated diabetic microvascular damage. Invest Ophthalmol Vis Sci. 2013;54: 2373-2383.
72. Lee H, Lin CI, Liao JJ, et al. Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF-kappaB-dependent mechanism. Am J Physiol Cell Physiol. 2004;287: C1657-C1666.
73. Wojciak-Stothard B, Williams L, Ridley AJ. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol. 1999;145: 1293-1307.
74. Fazal F, Bijli KM, Minhajuddin M, Rein T, Finkelstein JN, Rahman A. Essential role of cofilin-1 in regulating thrombininduced RelA/p65 nuclear translocation and intercellular adhesion molecule 1 (ICAM-1) expression in endothelial cells. J Biol Chem. 2009;284: 21047-21056.
75. Anwar KN, Fazal F, Malik AB, Rahman A. RhoA/Rho-associated kinase pathway selectively regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via activation of I kappa B kinase beta and phosphorylation of RelA/p65. J Immunol. 2004;173: 6965-6972.
76. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010;26: 105-110.
77. Van de Velde S, Van Bergen T, Sijnave D, et al. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014;55: 1006-1016.
78. Wang SK, Chang RT. An emerging treatment option for glaucoma: Rho kinase inhibitors. Clin Ophthalmol. 2014;8: 883-890.
79. Michels S, Schmidt-Erfurth U, Rosenfeld PJ. Promising new treatments for neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2006;15: 779-793.
80. Tsapara A, Luthert P, Greenwood J, Hill CS, Matter K, Balda MS. The RhoA activator GEF-H1/Lfc is a transforming growth factor-beta target gene and effector that regulates alphasmooth muscle actin expression and cell migration. Mol Biol Cell. 2010;21: 860-870.
81. Nishikimi T, Matsuoka H. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis. J Pharmacol Sci. 2006;100: 22-28.
82. Cao J, Zhao L, Li Y, et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest Ophthalmol Vis Sci. 2010;51: 6009-6017.
83. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27: 787-794.